Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change
Poolbeg Pharma PLC (AIM:POLB) to attend HC Wainwright Global Investment Conference, New York City, USA
12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model.
Poolbeg Pharma PLC (AIM:POLB) Interim results for the six months to 30 June 2022
Significant strategic and operational progress
Poolbeg Pharma – Climate crisis is creating the perfect storm for infectious diseases
As global temperatures have gone up, so too have outbreaks of many infectious illnesses. Climate change has exacerbated 218 out of 375 conditions
Poolbeg Pharma PLC (AIM:POLB) Notice of Results
31 August 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, will announce
Poolbeg Pharma plc (AIM:POLB) Major milestone reached as POLB 001 human challenge clinical trial ready to commence
Regulatory approval gives green light for trial to proceed 20 July 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company
Poolbeg Pharma PLC (AIM:POLB) Project update for AI model of RSV data
OneThree Biotech completes build and optimisation of AI model for RSV data – results to come in H2
Poolbeg Pharma PLC (AIM:POLB) US patents granted for POLB 001 and POLB 002
Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Poolbeg Pharma PLC (AIM:POLB) GMP manufacturing contract signed
Update on POLB 001 Clinical Development
Poolbeg Pharma PLC (AIM:POLB) Attendance at European Melioidosis Congress
Poolbeg to engage with key international stakeholders at congress as it develops an intramuscular Melioidosis vaccine candidate
Poolbeg Pharma PLC (AIM:POLB) Distribution in Specie update
Results of the proposal to purchase shares from Distribution in Specie shareholders
